Acute Lymphoblastic Leukemia Clinical Trial
Official title:
T-Cell Replete Haploidentical Donor Hematopoietic Stem Cell Plus Natural Killer (NK) Cell Transplantation in Patients With Hematologic Malignancies Relapsed or Refractory Despite Previous Allogeneic Transplant
The primary aim of this protocol is to evaluate if the one-year survival is significantly improved in the group of patients who receive a T-cell replete haploidentical donor hematopoietic cell transplant (HCT) with a novel reduced intensity conditioning regimen. Study population will consist of patients (21 years or under) with hematologic malignancies that have relapsed or are refractory after prior allogeneic transplant. Toxicity will be evaluated by the rate of transplant related mortality and the rates of moderate and severe graft-versus-host disease (GvHD) at day 100. The investigators will describe event-free, and disease-free survival at one year, as well as the rates of hematopoietic recovery and donor engraftment and study comprehensively immune reconstitution following T-cell replete haploidentical transplantation.
Status | Terminated |
Enrollment | 34 |
Est. completion date | December 2015 |
Est. primary completion date | December 2015 |
Accepts healthy volunteers | No |
Gender | Both |
Age group | N/A to 21 Years |
Eligibility |
Inclusion Criteria - for transplant recipient: - Age less than 21 years. - One of the following hematologic malignancies that has relapsed or remains refractory after prior allogeneic HCT: - Acute lymphoblastic leukemia (ALL) - Acute myeloid leukemia (AML) (including myeloid sarcoma) - Chronic myelogenous leukemia (CML), juvenile myelomonocytic leukemia (JMML), myelodysplastic syndrome (MDS), Hodgkin or non-Hodgkin lymphoma (NHL) - Has a suitable single haplotype matched (= 3 of 6) family member donor. - Does not have any other active malignancy other than the one for which this transplant is indicated. - If prior central nervous system (CNS) leukemia, it must be treated and have no evidence of CNS disease - Does not have current uncontrolled bacterial, fungal, or viral infection per the judgment of the principal investigator. - Patient must fulfill pre-transplant evaluation: - Left ventricular ejection fraction greater than 40%, or shortening fraction greater than or equal to 25%. - Creatinine clearance or Glomerular Filtration Rate of =70 ml/min/1.73m^2. - Forced vital capacity (FVC) = 40% of predicted value; or pulse oximetry = 92% on room air if patient is unable to perform pulmonary function testing. - Karnofsky or Lansky (age-dependent) performance score = 50. - Total bilirubin = 1.5 times the upper limit of normal for age. - Alanine aminotransferase (ALT) = 3 times the upper limit of normal for age. - Not pregnant. If female with child bearing potential, must be confirmed by negative serum or urine pregnancy test within 14 days prior to enrollment. - Not breast feeding. - Does not have active acute bronchiolitis obliterans or bronchiolitis obliterans organizing pneumonia. Inclusion Criteria - for donor: - At least single haplotype matched (= 3 of 6) family member, - At least 18 years of age. - Human immunodeficiency virus (HIV) negative. - Not pregnant as confirmed by negative serum or urine pregnancy test within 14 days prior to enrollment (if female). - Not breast feeding. - A suitable donor is identified as either: - Has completed the process of donor eligibility determination as outlined in 21 CFR 1271 and agency guidance; OR - Does not meet 21 CFR 1271 eligibility requirements, but has a declaration of urgent medical need completed by the principal investigator or physician sub-investigator per 21 CFR 1271. Exclusion Criteria: - Does not meet above inclusion criteria. |
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Country | Name | City | State |
---|---|---|---|
United States | St. Jude Children's Research Hospital | Memphis | Tennessee |
Lead Sponsor | Collaborator |
---|---|
St. Jude Children's Research Hospital | Assisi Foundation |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | One-year survival | Evaluate the percentage of participants alive at 1 year | One year post transplant | No |
Secondary | Incidence of Malignant Relapse | Estimate the incidence of malignant relapse at one-year post-transplantation. | One year post transplantation. | No |
Secondary | Event-Free Survival (EFS) | Estimate the EFS at one-year post-transplantation. EFS is defined as the time from date of HCT to the minimum value of date of last follow-up, date of relapse, and date of death due to any cause. All participants surviving at the time of analysis will be censored. | one year post transplant | No |
Secondary | Disease-Free Survival (DFS) | Estimate the DFS at one-year post-transplantation. DFS is defined as the time from date of HCT to the minimum value of date of last follow-up, date of relapse, and date of death due to relapse. All participants surviving at the time of analysis and those who die due to other causes will be censored at the time of their event. | one year post transplant | No |
Secondary | Incidence and severity of acute and chronic Graft Versus Host Disease (GVHD) | Estimate incidence of acute and chronic GVHD and describe the severity of acute and chronic GVHD. | 100 days post transplant | Yes |
Secondary | Rate of transplant related mortality and transplant related morbidity | Estimate the incidence of transplant related mortality and transplant related morbidity in the first 100 days after transplantation. | 100 days post transplant | Yes |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05400122 -
Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer
|
Phase 1 | |
Recruiting |
NCT05772000 -
Clinical Significance of Occult Central Nervous System Localization
|
||
Recruiting |
NCT05618041 -
The Safety and Efficay Investigation of CAR-T Cell Therapy for Patients With Hematological Malignancies
|
N/A | |
Active, not recruiting |
NCT03844048 -
An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial
|
Phase 3 | |
Active, not recruiting |
NCT03114865 -
A Study of Blinatumomab in Patients With Pre B-cell ALL and B-cell NHL as Post-allo-HSCT Remission Maintenance
|
Phase 1/Phase 2 | |
Not yet recruiting |
NCT06308588 -
Phase II Study of the Combination of Blinatumomab and Asciminib in Patients With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
|
Phase 2 | |
Recruiting |
NCT05579132 -
A Phase Ib/II Study of CN201 in Precursor B-cell Acute Lymphoblastic Leukemia
|
Phase 1/Phase 2 | |
Recruiting |
NCT04904588 -
HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide
|
Phase 2 | |
Terminated |
NCT02231853 -
Phase I/II Trial of Early Infusion of Rapidly-generated Multivirus Specific T Cells (MVST) to Prevent Post Transplant Viral Infections
|
Phase 1 | |
Recruiting |
NCT04969601 -
Anti-Covid-19 Vaccine in Children With Acute Leukemia and Their Siblings
|
Phase 1/Phase 2 | |
Recruiting |
NCT06195891 -
Orca-T Following Chemotherapy and Total Marrow and Lymphoid Irradiation for the Treatment of Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia or Myelodysplastic Syndrome
|
Phase 1 | |
Withdrawn |
NCT02815059 -
Study of Pts With Philadelphia Chromosome-Pos ALL With Comb of Ibrutinib, Dasatinib, and Prednisone
|
Phase 1 | |
Completed |
NCT00390793 -
Combination Chemotherapy and Dasatinib in Treating Participants With Philadelphia Positive or BCR-ABL Positive Acute Lymphoblastic Leukemia.
|
Phase 2 | |
Recruiting |
NCT05866887 -
Insomnia Prevention in Children With Acute Lymphoblastic Leukemia
|
N/A | |
Completed |
NCT00026780 -
Eligibility Screening for a NCI Pediatric Oncology Branch Research Study
|
||
Completed |
NCT04666025 -
SARS-CoV-2 Donor-Recipient Immunity Transfer
|
||
Not yet recruiting |
NCT06350994 -
Early Assessment of Cardiac Function After Treatment With CAR-T Cells
|
||
Withdrawn |
NCT04282174 -
CD34+ Enriched Transplants From HLA-Compatible Patients With Hematologic Malignancies
|
Phase 2 | |
Not yet recruiting |
NCT04488237 -
Vitamin D and Methotrexate Adverse Effects
|
||
Completed |
NCT02544438 -
Study Evaluating the Safety and Efficacy of Astarabine in Acute Myeloid Leukemia or Acute Lymphoblastic Leukemia
|
Phase 1/Phase 2 |